Purpose: This study was designed to determine the feasibility and safety of ultrasound-guided transhepatic radiofrequency ablation (RFA) of masses in the right kidney.
Methods: Between June 2001 and December 2011, 18 patients who underwent transhepatic renal RFA procedures to treat 19 tumors were retrospectively identified. Complications (Clavien-Dindo classification system) and local tumor control were evaluated for all patients.
Results: Median maximal diameter of the treated renal tumors was 1.9 (range 1.1-4.3) cm. No major complication developed during any of the procedures. No hepatic tumor seeding was identified during imaging follow-up. There was a single technical failure (5.3%). Median cross-sectional imaging follow-up was 28 (range 3-121) months. Primary technique failure (local recurrence) occurred in 1 of the 16 tumors with follow-up imaging (5.3%).
Conclusions: Percutaneous ultrasound-guided transhepatic RFA of renal neoplasms is technically feasible, effective, and associated with a low rate of complications. The transhepatic approach may allow safe ablation of renal tumors that would otherwise be difficult to treat.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00270-013-0716-x | DOI Listing |
World J Gastrointest Surg
December 2024
Department of Outpatient, Puer People's Hospital, Puer 665000, Yunnan Province, China.
Malignant obstructive jaundice (MOJ) encompasses a range of diseases stemming from malignant tumors such as cholangiocarcinoma, pancreatic cancer, and primary liver cancer, among others, which cause obstruction in both intra- and extra-hepatic bile ducts. This obstruction may lead to elevated bilirubin levels, hepatic function impairment, and a low rate of successful surgical resection in clinical settings. There are various minimally invasive treatment options for MOJ, including endoscopic biliary drainage, ultrasound-guided procedures, and percutaneous biliary tract puncture drainage.
View Article and Find Full Text PDFCardiovasc Intervent Radiol
January 2025
Department of Gastroenterology and Hepatology, Zhongnan Hospital of Wuhan University, No. 169, Donghu Road, Wuchang District, Wuhan, 430071, Hubei Province, China.
Purpose: This study aimed to explore a modified direct intrahepatic portocaval shunt (DIPS) technique as an alternative approach for patients with portal vein occlusion (PVO) and cirrhosis who were not candidates for traditional transjugular intrahepatic portosystemic shunt (TIPS) due to anatomical challenges.
Technique: Three patients with esophageal or gastric fundus variceal hemorrhage complicated by severe PVO were treated using innovative DIPS approaches. Preoperative contrast-enhanced computed tomography was employed to assess anatomical feasibility.
World J Gastrointest Surg
November 2024
Department of Interventional Therapy, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
In a recent issue of the , a meta-analysis investigated the safety and efficacy of electrocautery-enhanced lumen-apposing metal stent (ECE-LAMS) implantation for managing malignant biliary obstruction following failed endoscopic retrograde cholangiopancreatography. This manuscript endeavors to offer a comprehensive look at the progression of endoscopic ultrasound-guided biliary drainage (EUS-BD) technologies, weighing their merits and drawbacks against traditional percutaneous methods. Several meta-analyses and randomized controlled trials have compared the performance of EUS-BD and percutaneous transhepatic cholangiodrainage (PTCD).
View Article and Find Full Text PDFScand J Gastroenterol
December 2024
Division of Gastroenterology and Nutrition, University of Texas Health Science Center, San Antonio, TX, USA.
World J Gastrointest Surg
October 2024
Department of Surgery, National Hospital Organization Iwakuni Clinical Center, Iwakuni 740-8510, Yamaguchi, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!